Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy.

Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R, Longo VD.

Sci Transl Med. 2012 Mar 7;4(124):124ra27. doi: 10.1126/scitranslmed.3003293. Epub 2012 Feb 8.

2.

Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.

Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8215-20. doi: 10.1073/pnas.0708100105. Epub 2008 Mar 31.

3.

Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression.

Brandhorst S, Wei M, Hwang S, Morgan TE, Longo VD.

Exp Gerontol. 2013 Oct;48(10):1120-8. doi: 10.1016/j.exger.2013.02.016. Epub 2013 Feb 21.

4.

Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.

Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD.

Cancer Res. 2010 Feb 15;70(4):1564-72. doi: 10.1158/0008-5472.CAN-09-3228. Epub 2010 Feb 9.

5.

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Croucher JL, Iyer R, Li N, Molteni V, Loren J, Gordon WP, Tuntland T, Liu B, Brodeur GM.

Cancer Chemother Pharmacol. 2015 Jan;75(1):131-41. doi: 10.1007/s00280-014-2627-1. Epub 2014 Nov 14.

6.

Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.

Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA.

BMC Cancer. 2012 Dec 4;12:571. doi: 10.1186/1471-2407-12-571.

7.

In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4).

Raffaghello L, Zuccari G, Carosio R, Orienti I, Montaldo PG.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3485-93.

8.

Fasting and differential chemotherapy protection in patients.

Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD.

Cell Cycle. 2010 Nov 15;9(22):4474-6. Epub 2010 Nov 15.

9.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
10.

Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models.

Bianchi G, Martella R, Ravera S, Marini C, Capitanio S, Orengo A, Emionite L, Lavarello C, Amaro A, Petretto A, Pfeffer U, Sambuceti G, Pistoia V, Raffaghello L, Longo VD.

Oncotarget. 2015 May 20;6(14):11806-19.

11.

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.

Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL.

Cancer Chemother Pharmacol. 2011 Aug;68(2):325-35. doi: 10.1007/s00280-010-1486-7. Epub 2010 Oct 24.

12.

In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.

Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ.

J Natl Cancer Inst. 2010 Jun 2;102(11):758-70. doi: 10.1093/jnci/djq125. Epub 2010 May 12.

13.

Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.

Li Z, Yan S, Attayan N, Ramalingam S, Thiele CJ.

Clin Cancer Res. 2012 Jul 1;18(13):3603-15. doi: 10.1158/1078-0432.CCR-11-3321. Epub 2012 May 1.

14.

Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.

Eilon GF, Gu J, Slater LM, Hara K, Jacobs JW.

Cancer Chemother Pharmacol. 2000;45(3):183-91.

PMID:
10663635
15.

The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Pledgie-Tracy A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA, Davidson NE.

Cancer Chemother Pharmacol. 2010 May;65(6):1067-81. doi: 10.1007/s00280-009-1112-8. Epub 2009 Aug 30.

16.

The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse.

Huang SM, Hsu PC, Chen MY, Li WS, More SV, Lu KT, Wang YC.

Int J Cancer. 2012 Aug 1;131(3):722-32. doi: 10.1002/ijc.26401. Epub 2011 Oct 20.

17.

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway.

Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D, Al-Alwan M.

Br J Cancer. 2014 Oct 14;111(8):1552-61. doi: 10.1038/bjc.2014.453. Epub 2014 Aug 12.

18.

Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo.

Attoub S, Sperandio O, Raza H, Arafat K, Al-Salam S, Al Sultan MA, Al Safi M, Takahashi T, Adem A.

Fundam Clin Pharmacol. 2013 Oct;27(5):557-69. doi: 10.1111/j.1472-8206.2012.01056.x. Epub 2012 Jul 13.

PMID:
22788741
19.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012. Epub 2010 Jun 22.

Supplemental Content

Support Center